EU Panel Likes Two Cancer Drugs, Drops One

Two new cancer drugs were recommended for approval, and one had its marketing authorization withdrawn at the October meeting of the European Medicines Agency's advisory panel.

Related Keywords

Boston ,Massachusetts ,United States ,Ireland ,Aditya Bardia ,Gilead Sciences Ireland ,Hospital Cancer Center ,European Medicines Agency ,Drug Administration ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Massachusetts General Hospital Cancer Center ,Anal Cancer Drug ,Gilead Sciences ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Squamous Carcinoma ,Cancer ,Alignant Neoplasia ,Arcinoma ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Chemotherapy ,Non Small Cell Lung Cancer ,Nsclc ,Drug Regulation ,Biologic Therapy ,United Kingdom Site Content ,Anal Cancer ,Europe ,European ,Us Food And Drug Administration ,